Literature DB >> 3894139

Platelet sensitivity in vitro to adenosine-5'-diphosphate and prostacyclin and diabetic retinopathy.

T M Davis, E Bown, R C Turner.   

Abstract

Platelet sensitivity to adenosine diphosphate and prostacyclin in diabetes has been assessed using collision theory and the concept of 'sticking probability' (the probability of particle union). Twenty Type 1 (insulin-dependent) diabetic men (10 with no or minimal retinopathy and a matched group of 10 with proliferative retinopathy) and 10 age-matched nondiabetic men were studied. Platelets from the 20 diabetic patients required, on average, 37% less adenosine diphosphate to achieve a sticking probability of 0.5 (ED50) compared with platelets from the non-diabetic subjects (medians 1.50 and 0.95 mumol/l, respectively; p less than 0.01). The platelet prostacyclin response was assessed by the dissociation constant (Ki) for inhibition of adenosine diphosphate-induced aggregation. Platelets from the diabetic patients had similar prostacyclin sensitivity to those from the non-diabetic subjects (medians 0.42 and 0.42 respectively). Diabetic patients with and without retinopathy had similar platelet sensitivity to both adenosine diphosphate and prostacyclin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3894139     DOI: 10.1007/bf00271684

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  10 in total

1.  Decreased vascular prostacyclin in juvenile-onset diabetes.

Authors:  K Silberbauer; G Schernthaner; H Sinzinger; H Piza-Katzer; M Winter
Journal:  N Engl J Med       Date:  1979-02-15       Impact factor: 91.245

2.  Analysis of platelet aggregation using particle collision theory.

Authors:  T M Davis; E Bown
Journal:  Am J Physiol       Date:  1983-12

Review 3.  Platelet function in diabetes mellitus.

Authors:  J A Colwell; P V Halushka
Journal:  Br J Haematol       Date:  1980-04       Impact factor: 6.998

4.  Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics.

Authors:  G Davì; G B Rini; M Averna; S Novo; G Di Fede; A Pinto; A Notarbartolo; A Strano
Journal:  Thromb Res       Date:  1982-06-01       Impact factor: 3.944

Review 5.  Hematologic alterations in diabetes mellitus.

Authors:  R L Jones; C M Peterson
Journal:  Am J Med       Date:  1981-02       Impact factor: 4.965

6.  Platelets from diabetic subjects show diminished sensitivity to prostacyclin.

Authors:  D J Betteridge; K E El Tahir; J P Reckless; K I Williams
Journal:  Eur J Clin Invest       Date:  1982-10       Impact factor: 4.686

7.  In-vitro venous prostacyclin production, plasma 6-keto-prostaglandin F1 alpha concentrations, and diabetic retinopathy.

Authors:  T M Davis; E Bown; D R Finch; M D Mitchell; R C Turner
Journal:  Br Med J (Clin Res Ed)       Date:  1981-04-18

8.  Hyperglycaemia and diabetes mellitus.

Authors:  R J Jarrett; H Keen
Journal:  Lancet       Date:  1976-11-06       Impact factor: 79.321

9.  Elevated beta-thromboglobulin levels and circulating platelet aggregates in diabetic microangiopathy.

Authors:  F E Preston; J D Ward; B H Marcola; N R Porter; W R Timperley; B C O'Malley
Journal:  Lancet       Date:  1978-02-04       Impact factor: 79.321

Review 10.  Prostaglandins, platelets, and atherosclerosis.

Authors:  R J Gryglewski
Journal:  CRC Crit Rev Biochem       Date:  1980
  10 in total
  1 in total

1.  Thromboxane production and platelet aggregation in type 2 diabetes mellitus without vascular complications.

Authors:  K P Ratzmann; E Schimke; A Beitz; R Hildebrandt; C Taube
Journal:  Klin Wochenschr       Date:  1991-09-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.